Thrombocytopenia in the neonate

Area of Science:

• Neonatal Hematology
• Pediatric Critical Care
• Transfusion Medicine

Background:

• Thrombocytopenia is a common hematological issue in neonates, impacting at least 25% of neonatal intensive care unit (NICU) admissions.
• Traditional classifications of neonatal thrombocytopenia are less practical than newer, timing-based (early vs. late onset) approaches for diagnosis and management.
• Platelet transfusion is the primary treatment, but its clinical efficacy and safety in neonates remain unproven, with some studies suggesting potential adverse effects like increased mortality.

Purpose of the Study:

• To review recent advancements in understanding neonatal thrombocytopenia.
• To explore the prevalence, causes, and pathogenesis of thrombocytopenia in newborns.
• To discuss the clinical consequences and current developments in platelet transfusion for neonatal thrombocytopenia.

Main Methods:

• Literature review of recent progress in neonatal thrombocytopenia.
• Analysis of classifications based on the timing of thrombocytopenia onset.
• Examination of studies on the clinical outcomes and adverse effects of platelet transfusions in neonates.

Main Results:

• No definitive clinical benefit of platelet transfusion in neonatal thrombocytopenia has been established.
• Platelet transfusions may be associated with adverse outcomes, including increased mortality, varying by neonatal subgroups.
• Significant variations exist in transfusion practices across different geographical regions and neonatal units.

Conclusions:

• The clinical benefit of platelet transfusion for neonatal thrombocytopenia is not supported by current evidence.
• Adverse effects of platelet transfusion in neonates warrant careful consideration and further investigation.
• Standardized diagnostic and management strategies, informed by recent research, are needed for neonatal thrombocytopenia.